2,4-dichloro-6-propyl-[1,3,5]triazine | 30894-73-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 三嗪类
• 英文名称: 2,4-dichloro-6-propyl-[1,3,5]triazine
• 英文别名: Dichlor-propyl-[1,3,5]triazin；2,4-Dichloro-6-propyl-1,3,5-triazine
• CAS: 30894-73-6
• 化学式: C₆H₇Cl₂N₃
• mdl: MFCD15203620
• 分子量: 192.048
• InChiKey: VGVDKHQHGQNHLT-UHFFFAOYSA-N

物化性质

• 沸点：
  98 °C(Press: 15 Torr)
• 密度：
  1.349±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  38.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2,4-dichloro-6-propyl-[1,3,5]triazine 在 potassium carbonate 作用下， 以 甲醇 、 氯仿 为溶剂， 反应 4.0h， 生成 2-methoxy-4-morpholin-4-yl-6-propyl-[1,3,5]triazine
  参考文献：
  名称：

  Studies on Heterocyclic Compounds. II. Syntheses of 1, 3, 5-Triazine Derivatives and Their Pharmacological Activities.(2)

  摘要：

  DOI：

  10.1248/yakushi1947.95.5_512
• 作为产物：
  描述：

  三聚氯氰 、 丙基氯化镁 以 四氢呋喃 、 乙醚 为溶剂， 生成 2,4-dichloro-6-propyl-[1,3,5]triazine
  参考文献：
  名称：

  Anarchy in the solid state: structural dependence on glass-forming ability in triazine-based molecular glasses

  摘要：

  We have recently shown that molecular glasses, small molecules capable of readily forming glassy solids as opposed to crystals, can be designed by exploiting molecular association through strong and directional intermolecular interactions, as exemplified by several members of the bis(mexylantino)triazine family. Herein, 43 new bis(mexylamino)triazine derivatives were synthesized, 31 of which have been found to spontaneously form glassy phases and did not crystallize upon heating. Crown Copyright (C) 2009 Published by Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2009.07.026

文献信息

• Synthesen mit Cyanursäurechlorid
  作者：R. Hirt、H. Nidecker、R. Berchtold、G. Schönholzer

  DOI：10.1002/hlca.19500330536

  日期：——

  die Darstellung einiger Monoaminotriazine-(1,3,5) beschrieben, einerseits durch Hydrierung der entsprechenden Dichloraminotriazine, anderseits durch Umsetzung des leichter erhältlichen Phenoxytriazins mit Aminen. Daneben werden einige Alkyl-dichlortriazine und deren Umsetzung zu Alkylamino-alkyltriazinen beschrieben. Die Alkylamino-triazine können am externen N mittels Natriumamid zu tertiären Basen alkyliert

  它描述了一些单氨基三嗪（1,3,5）的制备，一方面是通过将相应的二氯氨基三嗪氢化，另一方面是通过使更容易获得的苯氧基三嗪与胺反应来制备。另外，描述了一些烷基二氯三嗪及其向烷基氨基-烷基三嗪的转化。可以使用酰胺钠将烷基氨基三嗪烷基化至外部N上的叔碱。
• Phosphodiesterase 4 inhibitors as airways smooth muscle relaxant agents: synthesis and biological activities of triazine derivatives
  作者：F Leroux、B.J van Keulen、J Daliers、N Pommery、J.P Hénichart

  DOI：10.1016/s0968-0896(98)00266-1

  日期：1999.3

  A series of triazine derivatives was synthesized. The compounds were evaluated for tracheal smooth muscle relaxant and type 4 phosphodiesterase inhibitory activities. A highly significant correlation was observed between the two effects. Two compounds exhibited potent relaxant activity (EC50: 17 and 24 nM) and might be useful for the treatment of asthma.

  合成了一系列三嗪衍生物。评价该化合物的气管平滑肌松弛剂和4型磷酸二酯酶抑制活性。在两种效应之间观察到高度显着的相关性。两种化合物表现出强大的松弛活性（EC50：17和24 nM），可能对哮喘的治疗有用。
• 2-amino-4-morpholino-6-propyl-1,3,5-triazines
  申请人：U C B S.A.

  公开号：US04956367A1

  公开（公告）日：1990-09-11

  New 2-amino-4-morpholino-6-propyl-1,3,5-triazines having the formula ##STR1## wherein R.sub.1 is hydrogen, alkyl, aralkyl or acetyl, R.sub.2 is hydroxyl, hydroxyalkyl, alkoxyalkyl, dialkylamino, arylhydroxyalkyl, (hydroxy-cycloalkyl)alkyl, alkanoyloxyalkyl, benzoyloxyalkyl, phenylacetyloxyalkyl, aminocarbonyloxyalkyl, COR.sub.3 or CONR.sub.4 R.sub.5, or NR.sub.1 R.sub.2 =(hydroxyalkyl)alkyleneimino, R.sub.3 =alkyl, aryl, haloaryl, alkylaryl, alkoxyaryl, aralkyl or aryloxy, R.sub.4 =R.sub.5 =hydrogen or alkyl, alkyl, alkoxy and alkanoyloxy having 1 to 4 carbon atoms, cycloalkyl and alkyleneimino having 4 to 6 carbon atoms. Moreover, when R.sub.1 is acetyl, R.sub.2 is acetoxyalkyl. Processes for the preparation thereof and pharmaceutical compositions containing the same are also given. In particular, these compounds are useful for the treatment of cognitive and behavioral disorders associated with aging and dementia syndromes, e.g. those associated with Alzheimer's disease.

  新的2-氨基-4-吗啡基-6-丙基-1,3,5-三嗪具有以下式子：##STR1## 其中R.sub.1是氢，烷基，芳基烷基或乙酰基，R.sub.2是羟基，羟基烷基，烷氧基烷基，二烷基氨基，芳基羟基烷基，(羟基-环烷基)烷基，烷酰氧基烷基，苯甲酰氧基烷基，苯乙酰氧基烷基，氨基羰氧基烷基，COR.sub.3或CONR.sub.4 R.sub.5，或NR.sub.1 R.sub.2 =(羟基烷基)烷基亚胺基，R.sub.3 =烷基，芳基，卤代芳基，烷基芳基，烷氧基芳基，芳基烷基或芳氧基，R.sub.4 =R.sub.5 =氢或烷基，烷基，烷氧基和烷酰氧基具有1到4个碳原子，环烷基和烷基亚胺基具有4到6个碳原子。此外，当R.sub.1为乙酰基时，R.sub.2为乙酰氧基烷基。还给出了其制备方法和含有它们的药物组合物。特别地，这些化合物对于治疗与衰老和痴呆综合症相关的认知和行为障碍，例如与阿尔茨海默病相关的障碍，非常有用。
• Preventives or remidies for alzheimer's disease or amyloid protein fibrosis inhibitors containing nitrogen-containing heteroaryl compounds
  申请人：Meguro Masaki

  公开号：US20050054732A1

  公开（公告）日：2005-03-10

  The present invention relates to preventives or remedies for Alzheimer's disease, or to amyloid protein fibril-formation inhibitors, which include as an active ingredient a compound of general formula (I) below or a pharmacologically permitted salt thereof; and also to nitrogen-containing heteroaryl derivatives having specific substituents, or pharmacologically permitted salts thereof, which are valuable as preventives or remedies for Alzheimer's disease, or as amyloid protein fibril-formation inhibitors: (where, R 1 and R 2 are H or alkyl; Z 1 and Z 2 are H, alkyl, alkoxy, haloalkyl or halogeno; Z 3 is alkoxy, SH, alkylthio, NH 2 , mono- or di-alkylamino, OH or halogeno; Z 4 and Z 5 are H or halogeno; and A is 4,6-pyrimidine-1,3-diyl, 1,3,5-triazine-2,6-diyl, etc).

  本发明涉及预防或治疗阿尔茨海默病的药物或药物，或β淀粉样蛋白纤维形成抑制剂，其中包括通式（I）下的化合物或其药学上允许的盐作为活性成分；还涉及具有特定取代基的含氮杂环衍生物或其药学上允许的盐，其作为防治阿尔茨海默病的药物或β淀粉样蛋白纤维形成抑制剂具有价值：（其中，R1和R2是H或烷基；Z1和Z2是H，烷基，烷氧基，卤代烷基或卤素基；Z3是烷氧基，SH，烷硫基，NH2，单或双烷基氨基，OH或卤素基；Z4和Z5是H或卤素基；A是4,6-嘧啶-1,3-二基，1,3,5-三嗪-2,6-二基等）。
• Preventives or remedies for Alzheimer's disease, or amyloid protein fibril-formation inhibitors, which include a nitrogen-containing heteroaryl compound
  申请人：Meguro Masaki

  公开号：US20080182846A1

  公开（公告）日：2008-07-31

  The present invention relates to preventives or remedies for Alzheimer's disease, or to amyloid protein fibril-formation inhibitors, which include as an active ingredient a compound of general formula (I) below or a pharmacologically permitted salt thereof; and also to nitrogen-containing heteroaryl derivatives having specific substituents, or pharmacologically permitted salts thereof, which are valuable as preventives or remedies for Alzheimer's disease, or as amyloid protein fibril-formation inhibitors: (where, R 1 and R 2 are H or alkyl; Z 1 and Z 2 are H, alkyl, alkoxy, haloalkyl or halogeno; Z 3 is alkoxy, SH, alkylthio, NH 2 , mono- or di-alkylamino, OH or halogeno; Z 4 and Z 5 are H or halogeno; and A is 4,6-pyrimidine-1,3-diyl, 1,3,5-triazine-2,6-diyl, etc).

  本发明涉及用于预防或治疗阿尔茨海默病的药物或疗法，或者用于抑制淀粉样蛋白纤维形成的药物，其中包括通式（I）所示的化合物或其药学上允许的盐作为活性成分；以及具有特定取代基的含氮杂环衍生物或其药学上允许的盐，它们对于预防或治疗阿尔茨海默病或作为淀粉样蛋白纤维形成抑制剂非常有价值。（其中，R1和R2为H或烷基；Z1和Z2为H、烷基、烷氧基、卤代烷基或卤素；Z3为烷氧基、SH、烷基硫醇、NH2、单烷基或二烷基氨基、OH或卤素；Z4和Z5为H或卤素；A为4,6-嘧啶-1,3-二基、1,3,5-三嗪-2,6-二基等）。